Morgan Stanley downgraded Roche (RHHBY) to Underweight from Equal Weight with a price target of $39, down from $44. The firm sees downside to consensus estimates from competition, new launch setbacks and Roche’s upcoming “high risk” pipeline readouts. The company’s lack of pipeline momentum will likely continue into 2026, the analyst tells investors in a research note. Morgan Stanley believes the stock’s valuation “looking demanding.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche Holding AG Faces Growth Challenges Amidst Competition and Regulatory Risks, Downgraded to Underweight
- Trump Weekly: President says raising tariffs on India ‘substantially’
- Trump says separate tariff announcements coming for semi chips, pharmaceuticals
- Sonnet BioTherapeutics expands clinical evaluation of SON-1010 dose escalation
- Roche announces data from Phase 3 Portal study of Susvimo